Hansa Biopharma AB and its partner Medison Pharma announced that the Israeli Ministry of Health has approved Idefirix® for desensitization treatment of highly sensitized kidney transplant patients in Israel. Idefirix® is the first and only medicine licensed for desensitization of highly sensitized patients prior to kidney transplantation, allowing these patients to access a life-changing kidney transplantation from a deceased donor. Highly sensitized kidney patients have previously had very limited access to kidney transplants due to the lack of effective desensitization treatments, and they often have no alternative but to remain on long-term dialysis.

Long-term dialysis can place a significant burden on patients and on healthcare systems and is associated with a reduction in health-related quality of life and increased risk of mortality, hospitalizations and additional costs.